Insider Trading Arrangements |
3 Months Ended | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mar. 31, 2026
shares
| |||||||||||||||||||||||||||||||||||
| Trading Arrangements, by Individual | |||||||||||||||||||||||||||||||||||
| Material Terms of Trading Arrangement | Trading Plans or Rule 10b5-1 Trading Plans During the quarter ended March 31, 2026, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of our securities set forth in the table below.
* Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. ** "Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. *** Represents the maximum number of shares that may be sold pursuant to the . The number of shares to be sold was dependent on the satisfaction of certain conditions as set forth in the written plan. |
||||||||||||||||||||||||||||||||||
| Name | Sean Bohen, M.D., Ph.D. | ||||||||||||||||||||||||||||||||||
| Title | President and Chief Executive Officer | ||||||||||||||||||||||||||||||||||
| Rule 10b5-1 Arrangement Adopted | true | ||||||||||||||||||||||||||||||||||
| Adoption Date | March 3, 2026 | ||||||||||||||||||||||||||||||||||
| Expiration Date | June 8, 2027 | ||||||||||||||||||||||||||||||||||
| Arrangement Duration | 463 days | ||||||||||||||||||||||||||||||||||
| Aggregate Available | 705,000 | ||||||||||||||||||||||||||||||||||